Connect with us
  • Elysium

Tech

Fourier Intelligence – expanding excellence in rehab robotics

How the unicorn is sharing knowledge and technology through key strategic partnerships around the world

Published

on

With the expansion of Fourier Intelligence continuing at pace globally, and its rehabilitation robotics being used increasingly around the world, its international presence has never been stronger. 

But the true international nature of its business goes much further than the fact its technology is used around the globe. 

Through partnering with key locations and teams around the world, tech unicorn Fourier is showing what is possible by working alongside and developing the expertise and resources beyond its bases in Shanghai, Malaysia and recently-acquired headquarters in Zhangjiang Science City, known as the ‘Silicon Valley of the East’. 

And through such knowledge transfer between experts equally committed to delivering the means to improve people’s lives, Fourier’s mission to change what is possible in rehab robotics only increases. 

Its partnership with the University of Melbourne, finalised in 2019, is a key component in its international expansion.

Through the creation of the Robotics Laboratory, a joint initiative between the University and Fourier, the opportunities for innovation – and with it, opportunities for aspiring talent from across the continent – are being channelled into increasing rehab provision on an international scale. 

ArmMotus EMU

Led by Professor Denny Oetomo, a world-renowned figure in robotics, it played a leading role in the development and launch of the ArmMotus EMU – Fourier’s latest and next-gen robot, hailed as having the potential to redefine neurorehab. 

Working closely with Fourier experts in Singapore and Shanghai, the partnership enabled the EMU project, which had been in development for two years, to come to fruition and act as a beacon of what could be achieved through close co-operation on an international basis. 

And with a growing portfolio of robots – more than 20 are already commercially available, accruing  over 10 million usage hours so far, with a further 100 in development – and more recently-established global partnerships including with the Shirley Ryan AbilityLab in Chicago propelling its presence in the United States, Fourier’s success in Melbourne is clearly a winning formula. 

“I have always believed in a collaborative approach, there are no barriers or boundaries with technology, we are all humans on the same planet,” says Zen Koh, co-founder of Fourier Intelligence. 

“It is vital that we work with universities and hospitals to develop our technology further, for the benefit of patients and their rehabilitation. 

“The partnerships with Melbourne and Shirley Ryan AbilityLab are our first success stories and this is just the beginning. There will be more collaboration and hopefully, by working together, humankind can push the boundaries further.

“With Melbourne, this success sends a strong signal of how well we can work collaboratively, we can offer a very attractive arrangement – IP, technology, the strength of the Fourier supply chain, high-quality manufacturing at a low price. 

“We have that capability already in place – for others it would take years to develop, it may be successful, it may not. Fourier is sending a very strong signal to the world that we welcome such collaboration and can, through technology and knowledge transfer, bring ideas into reality.”

For Prof Oetomo, the formation of the partnership works very well on a practical level.

“This agreement has enabled us to work together on something much more than just a project, more than a Memorandum of Understanding. In this case, we signed an umbrella agreement which built a working relationship and a commitment to work together,” says Prof Oetomo, who studied as a postgraduate with Zen. 

“This included an IP agreement, the ability to design code, to collaborate on design. We ensured we eliminated a lot of the proprietary red tape from the very beginning. We’re all in this for the same reason – to help people’s lives – so we want to make doing that as simple as possible.

“So now, if we are working together on design and we need a part modifying, we can ask for the code for that. Or if they’re working on something and it’s easier to modify that in Shanghai, we can send the code. 

“We have built an open relationship, where we know and understand each other on both sides. Fourier are not so much a startup anymore, they’re a strong and successful partner who support us at the University.”

Professor Denny Oetomo

And through its close collaboration across the miles, its first project, the ArmMotus EMU, has become a key new addition to the global neurorehab market.  

As the world’s first 3D back-drivable upper limb rehabilitation robot – equipped with clinical intelligence and providing personalised therapy, technology-based solutions, coaching capabilities and remote monitoring – industry figures believe this has set a new benchmark for intelligent rehabilitation devices. 

“Current neurorehabilitation models primarily rely on extended hospital stays or regular therapy sessions which require close physical interactions between rehab professionals and patients,” says Zen. 

“The ongoing COVID-19 pandemic situation has challenged this model and as a result, many neurological patients are not receiving sufficient therapy. There is an urgent need to rethink conventional neurorehabilitation therapy.

“The new ArmMotus EMU provides that solution.”

The project, led by Prof Oetomo, saw close collaboration between teams in Singapore and Melbourne.

“What we do is so niche, it’s not well catered for, and we saw the opportunity here. The potential for what we can do has not yet been fully realised,” he says. 

“This is 3D movement which can accentuate vertical motion, and the facility now exists to collect the information to support that. Combined with the appropriate gravity compensation of the weight of the arm, patients with weak or little arm function can able to carry out therapy without exertion. 

“We did our research on this and have created something that addresses the points clinicians raise, such as they don’t have the time to work inaccessible equipment, or it’s too heavy to manage physically. If they don’t use it, then rehab for their patients is not going to happen. 

Alex Gu and Zen Koh

“Something else we will be working on collaboratively is a training programme in how best to use our robots for clinicians, how you can use them to be more targeted and more useful in interdisciplinary work.

“Clinicians are our close colleagues as leading professionals in their field but we don’t want them to get this new technology and then have to read a robotic manual on how to use it, they want a clinical one. So that is another project we are working on together.”

With the success of the Robotics Laboratory partnership showing the potential of international working, the adoption of technology during the past two years in particular has shown many other businesses how effectively global working and co-operation can be done. 

“The pandemic has indirectly propelled researchers to work via video conferencing, in the past this has not been fully embraced, but for us it is working well between our teams in Singapore, Shanghai, Zurich and America,” says Zen. 

“Previously, we would have had people from all over the world coming to a single location. By using technology, we can move forward quicker than expected, video conferencing is very useful in discussions, negotiations and brainstorming – although it is very important to continue to meet face to face for the final decisions, to touch the products, feel them and understand them. 

“But working remotely will continue to happen and I do think this has been a very, very positive point from the last two years, despite the pandemic, and we have all been able to move forward more innovatively.”

“Neurorehab tech is something we are working on as a whole world, and today the world is pretty small, there is a lot of online communication,” says Prof Oetomo. 

“Our partnership would have happened anyway, we did a lot of face to face visits at first back in 2018 and 2019 to build the relationship, but the use of technology has helped. 

“We have a network of close colleagues and we all talk with each other and share common equipment. It is much easier to run a multi-site test with the same robot and the same programme, then it can be more repeatable and easily comparable. 

“A lot of facilities were already out there, the technology infrastructure was there, there was a lot of Cloud storage for our drawings which we were using before the pandemic – but for people all over the world, the circumstances forced them to use it. 

“It may not necessarily be more enjoyable to always communicate virtually, or attend conferences that way, but it is much easier and that has a positive effect for sure. In the past, you’d invite a person to come out to Australia, and it would be a three or four day trip. Now, you can just dial them in and work around their time zone and that works fine. 

“People are now more accepting of these practices, which I think will benefit joint working for everyone, including ourselves.” 

Tech

Fourier Intelligence continues international collaboration

The rehab robotics pioneer has signed a MoU with Centro Europeo de Neurosciencias

Published

on

Rehab robotics unicorn Fourier Intelligence is continuing its work in advancing the fast-growing sector by forming a new partnership with Centro Europeo de Neurosciencias (CEN). 

The signing of the Memorandum of Understanding (MoU) will focus on the testing of new and existing rehabilitation robotic devices created by Fourier Intelligence. 

Fourier Intelligence robotics are already in use around the world, with testing and feedback undertaken continually to ensure they are best equipped to improve patients’ lives and deliver the highest standards of rehabilitation. 

With a track record of healthcare excellence and research, working alongside international partners, CEN already makes an important contribution on a global scale and will be a key partner in the further development of Fourier Intelligence’s portfolio of life-changing devices. 

The MoU is the latest to be signed by Fourier Intelligence with key global partners, as part of its commitment to working in collaboration with experts around the world to create world-leading rehab robotics. 

“The agreement of this MoU is another significant step in the ongoing development of rehabilitation robotics, which will improve patients’ lives,” says Zen Koh, co-founder and group deputy CEO of Fourier Intelligence. 

“CEN has an excellent international reputation and track record in healthcare and research, and we are delighted to partner with them in this way. The testing of new and existing Fourier Intelligence devices is critical to maximising patient outcomes, so this will be very important in achieving that.

“We believe collaboration is at the heart of developing this sector and making a difference in the lives of those who need this technology, and are very proud to have key partners around the world. Together, we will take this forward and make the positive change that is needed.”

Continue Reading

Tech

The patience of patients

Stroke survivor Lisa Beaumont reflects on her ongoing rehabilitation and the vital role NeuroProactive can play

Published

on

Rehabilitation cannot be rushed. Each patient needs to develop techniques to build the patience they need.

In Spring 2022, I faced the biggest setback in my rehabilitation journey so far. A problem with my leg splint meant that I was unable to walk for two to three months.

I learned plenty about myself during this interlude. While my orthotic was being replaced, I watched from my window while Spring became early Summer.  I could not leave my bedroom for several weeks. Most importantly, I learned about my techniques for managing my frustration with my situation.

I had plenty of time to reflect upon my situation and to consider ways that might avoid this situation happening for others. Access to digital solutions such as neuroproactive.com from the outset will offer solutions for the patients of the future. 

For the last eleven years I have focussed my energy on learning to walk again. Therefore, it took a substantial adjustment physically and mentally for me to adapt to being confined to one room without any possibility of walking anywhere. I chose to focus on two activities which were possible for me to do.

Firstly, I could still develop my cognitive rehabilitation through game-playing. I found several games I could play on my phone, including Wordle, Words with Friends and Solitaire. 

I realised that Solitaire, also known as the English card game Patience, makes a good analogy for any rehabilitation journey. There is only one player in the game, and you can win or lose depending on your actions and choices. You cannot speed up the pace of the game, but you at least know where you are.  

Likewise, in rehabilitation. Neuroproactive.com offers features that would have avoided some of my frustration this Spring. It enables speedy communication between clinicians and patients. I would have had an opportunity to track the progress of my replacement splint. And it would have been a single place for the orthotist, physiotherapist and district nurses to discuss my case.

I realised that a strength of neuroproactive.com is that it recognises the central role that a patient has in their rehabilitation journey.  Consequently, the platform validates the patient’s experiences by giving them the ability so see and to help manage the input they need from their team of clinicians.

The other second activity was that part of the physiotherapy that I could still do – exercises in bed and upper limb work.  My carers supported me by helping me to count and record my repetitions and by monitoring the quality of my movements.

How could neuroproactive.com have helped to improve my situation? My situation could potentially have been avoided through better
communication between my orthotist, physiotherapist, GP and my team of carers. Neuroproactive.com can act as a single shared space for each person to share updates and photos.  

As more practitioners gain access to, and familiarity with, Neuroproactive.com and its features, new and exciting ways to use it will emerge.

We’re in the process of rolling out Neuro ProActive to 31 NHS Trusts.

You can find out more online www.Neuroproactive.com or connect with us on Twitter @NeuroProActive.

Continue Reading

Spinal

ONWARD – making the impossible possible

CEO Dave Marver discusses its pioneering work in spinal cord injury and the new hope for people living with paralysis

Published

on

Professor Gregoire Courtine, Dr Jocelyne Bloch, Dave Marver

The concept of three people living with complete paralysis regaining the ability to walk independently is something that, in the very recent past, would have been dismissed as being impossible – but through the work of ONWARD, this one-time ‘impossibility’ is now becoming reality. 

For years, spinal cord injury has been regarded by many as the ‘graveyard of neuroscience’, where hope was in short supply and the outlook for those daring to dream of the day that may change was bleak. 

But now, through the efforts of pioneers who have led the research breakthroughs that are now shaping reality, the ability of technology to change lives is being seen by the whole world, with people watching in amazement as paralysed patients rediscover the ability to move. 

After being implanted with spinal stimulation technology developed by ONWARD – the first time its epidural electrical stimulation (EES) had been trialled in humans – all three participants who were part of the STIMO-BRIDGE trial were able to take steps independently within a single day.

After five months of rehabilitation, they were also able to use their legs to stand, walk, swim, and/or cycle. They also regained control of their trunk muscles. 

Such colossal steps forward in SCI are now giving new hope to people living with paralysis – and are helping to show, rather than being impossible, what could become the new possible for the future. 

“We were very pleased with the results of STIMO-BRIDGE, although we as a company are not going to be pleased with just impacting subjects in a clinical trial,” Dave Marver, CEO of ONWARD, tells NR Times. 

“Our job and our unique role is to scale these therapies so they can provide benefit to hundreds of thousands of people with spinal cord injury around the world. 

“These results show great promise, but we still have a tremendous amount of work to do to achieve our vision.” 

And for ONWARD, that vision is to change the lives of people living with SCI globally, to enable them to enjoy and live their lives in the ways that matter most to them. 

Established in 2014 to focus specifically on SCI, the venture has led truly groundbreaking research into this long-underserved area. 

Founded by neurosurgeon Dr Jocelyne Bloch and Professor Gregoire Courtine, Swiss-based ONWARD has taken decades of research and translational science to bring to fruition two viable commercial solutions. 

With its ARC EX and ARC IM devices, ONWARD – backed by many of the leading European life sciences venture capital investors – has led the charge on redefining the outlook for SCI patients. 

Its ARC IM, recently subject to the STIMO-BRIDGE trial, consists of an implantable pulse generator and lead that is placed near the spinal cord, controlled by wearable components and a smartwatch. A pivotal trial is set to begin within the next 12 to 18 months. 

The ARC EX is an external, non-invasive wearable stimulator and wireless programmer, which targets the rediscovery of upper body movement. Currently subject to the international Up-LIFT trial – the largest SCI trial of its kind – it completed enrolment of 65 participants ahead of schedule, despite the many challenges presented by the COVID-19 pandemic.

Currently being trialled at sites across the world – including in the NHS Greater Glasgow and Clyde (NHSGGC), as well as Neurokinex sites in England – the aim, pending necessary approvals, is for a commercial launch in the first half of 2023. 

But while the excitement at the potential of ONWARD is palpable, with the first introduction of its technology into rehabilitation centres across the United States, UK, France, Germany and the Netherlands potentially barely a year away, Dave is keen to ensure expectations remain realistic.  

“Certainly this will give hope to people, and I think the fact we enrolled all 65 subjects in Up-LIFT ahead of schedule, despite all the challenges of clinics closing and difficulties with quarantines and so forth, speaks to the enthusiasm that the clinical community has for this therapy,” he says.

“They have really embraced it, as the participants did in STIMO-BRIDGE. We, and they, are showing what is possible. 

“But I do think it’s important to not overstate it, I don’t want to create false hope, because these subjects really committed themselves to the therapy and to the rehabilitation process. 

“I think there is great potential that many people with paralysis will be able to stand again with the benefit of our therapies, maybe take some steps. But then it really depends on their particular circumstances and their overall level of health, their willingness to commit to rehabilitation, whether they can go further than that. 

“And, of course, not everyone with spinal cord injury, desires necessarily to walk again, they may have other priorities. And that’s why ONWARD is also committed to addressing other challenges that affect the quality of daily life, such as blood pressure and trunk control and use of better use of the upper extremities. 

“And then in the future, we’ll be looking at incontinence and restoration of sexual function, the whole battery of things that people with SCI have to contend with.”

Through its longstanding and deep-rooted commitment to the SCI community, ONWARD has secured relationships with of some of the world’s leading organisations in this area, including the International Spinal Research Trust and the Christopher & Dana Reeve Foundation. The latter has even become ONWARD shareholders, to help further its pioneering work. 

For Dave, while the word ‘pioneering’ is well-used, for ONWARD, it is also well-earned. 

“I think we are seen as pioneers in this area because we’ve chosen to focus on serving the spinal cord injury community,” he says. 

“It’s a smaller population than other populations with movement-related challenges, like stroke and Parkinson’s, for example. Most businesses orientate toward the largest potential markets, whereas our founders really had a passion for helping people with spinal cord injury. 

“And that remains the core vision, that was their raison d’être, and it’s with that commitment and determination that we have achieved such progress. 

“We haven’t partnered with existing spinal cord stimulation companies, we’ve developed our own technology platform that is built for the specific purpose of not stimulating the spinal cord for pain management, but stimulating the spinal cord to restore strength and function.

“But I think the progress we have made also reflects the close collaboration that we enjoy and value with our scientific partners. We have a group of people so committed and driven by our mission, which I think is why we make the progress we have done. 

“We develop that lead together in a very rigorous way, with our vision at the heart of that.”

Constantly looking to the next innovation and how its technologies can be even more beneficial to those who need them, ONWARD is also considering how, post-commercial launch, its ARC EX could be used remotely. 

“Later, we’ll be seeking approval for it to be used in people’s homes, so they can conduct periodic sessions maybe once or twice a week in their homes to continue gains that they have observed in the clinic, and build on those gains,” says Dave. 

“We’ll be looking at a successor study to Up-LIFT which would look at safety and performance when used in the home. 

“Without question, it’s important with spinal cord injury to be able to operate this technology, which is why we were keen to incorporate voice activation into the system. Both of our platforms can be programmed by the clinician, but in the future may be operated by and used by the injured with their voices. 

“But very importantly, we do our best to connect as frequently as possible with people with injury to inform the design of our product platforms, and inform our future direction as a company. 

“We consider ourselves part of the community, so that feedback to ensure the design of our technologies is really usable and accessible, in my view, is vitally important.”

And with such huge advances and new-found hope for the future, many conversations have turned to whether SCI may be curable. 

“I wouldn’t rule anything out, with human ingenuity and so forth, but what I would say is more realistic at this point is to have optimism – quite a bit of optimism – that movement and strength and function can improve, and in some cases, be restored with the benefit of therapies like ours,” says Dave. 

“Perhaps other therapies and technologies will emerge, if you look at how far we have come. But for us, our vision is to support the SCI community around the world through our therapies, and we’ll continue to do that. 

“We’re making steady progress across all areas of our plan, and while what we’re doing is difficult and complex, I’m confident we will come through.”

Continue Reading

Newsletter

Sign up for the NR Times newsletter
I would like to receive by email other offers, promotions and services from Aspect Publishing Ltd and its group companies.*

Trending